Indeed, the density of CD4+ and CD8+ tumor-infiltrating lymphocytes (TILs) was also remarkably increased in the ARID1A-deficient CRC tumors that received RT and CHK1 inhibitor treatment (Fig. 5F). Here, ARID1A is linked to neoplasm.